AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland
about
Video Q&A: what is ASIA? An interview with Yehuda Shoenfeld.Vaccinology in the third millennium: scientific and social challengesVaccination of healthcare workers: A reviewH5N1 vaccines in humansNarcolepsy: neural mechanisms of sleepiness and cataplexyFluad®-MF59®-Adjuvanted Influenza Vaccine in Older AdultsTargeted vaccine selection in influenza vaccinationProtection of young children from influenza through universal vaccination.Obstetrical and neonatal case definitions for immunization safety dataAutoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort studyGenomics and infectious disease: a call to identify the ethical, legal and social implications for public health and clinical practiceComputing limits on medicine risks based on collections of individual case reportsNational surveillance of influenza-associated encephalopathy in Japan over six years, before and during the 2009-2010 influenza pandemicGenome wide analysis of narcolepsy in China implicates novel immune loci and reveals changes in association prior to versus after the 2009 H1N1 influenza pandemicEuropean decision-maker perspective with regard to influenza prevention policies.Investing in Immunity: Prepandemic Immunization to Combat Future Influenza Pandemics.Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of age.Health and economic benefits of early vaccination and nonpharmaceutical interventions for a human influenza A (H7N9) pandemic: a modeling study2009 Pandemic influenza A virus subtype H1N1 vaccination in Africa--successes and challenges.Preclinical evaluation of Vaxfectin-adjuvanted Vero cell-derived seasonal split and pandemic whole virus influenza vaccinesIncreased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France.An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants.No serological evidence of influenza A H1N1pdm09 virus infection as a contributing factor in childhood narcolepsy after Pandemrix vaccination campaign in Finland.Extended antigen sparing potential of AS03-adjuvanted pandemic H1N1 vaccines in children, and immunological equivalence of two formulations of AS03-adjuvanted H1N1 vaccines: results from two randomised trials.Narcolepsy and A(H1N1)pdm09 vaccination: shaping the research on the observed signal.GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza.Narcolepsy as an immune-mediated diseaseRelative efficacy of AS03-adjuvanted pandemic influenza A(H1N1) vaccine in children: results of a controlled, randomized efficacy trial.Seasonal influenza vaccination and technologies.History of narcolepsy at Stanford University.Considerations for the rapid deployment of vaccines against H7N9 influenza.Clinical features of narcolepsy in children vaccinated with AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in England.Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children.Risk of narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec.Effectiveness of pandemic and seasonal influenza vaccines in preventing laboratory-confirmed influenza in adults: a clinical cohort study during epidemic seasons 2009-2010 and 2010-2011 in Finland.AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.Antigenic differences between AS03 adjuvanted influenza A (H1N1) pandemic vaccines: implications for pandemrix-associated narcolepsy risk.HLA-DPB1 and HLA class I confer risk of and protection from narcolepsyIncreased β-haemolytic group A streptococcal M6 serotype and streptodornase B-specific cellular immune responses in Swedish narcolepsy cases.
P2860
Q21245295-B86096EA-FDF7-44A6-89B1-44C64ACE762DQ24261399-CB248F50-4FD3-480E-A19A-CA1CCEA06FE3Q26796300-72508028-F47F-44A7-AE19-CFEACD72B9E1Q27000896-8053360E-840A-445D-8CC1-67D400A021A1Q27004322-07DD47A5-BB40-44CC-88C6-E9870D1E12C2Q27009478-20B6A72E-631F-4D83-817A-6B22FAE029D7Q27030899-DB0D9DDC-8CC7-43AB-9EC7-97C3EC1FC0F9Q27693242-1B248530-6AFE-4721-B5E1-F6B48D206F87Q28119706-DFE0BAA5-6F55-413F-8617-3E21111392DDQ28300023-4F89782E-993D-4E34-8726-62E842B0275AQ28543022-A7758079-B54A-437E-8FDF-8F2F7C6D9A9FQ28652138-F52AF11F-FA4A-48E7-B419-F030B7FF022BQ28709580-D67C14FC-6D7F-4D77-AF3B-90282330C4B9Q28943299-410395F4-5128-4D94-929F-34376B5AF033Q30151954-CA99E040-98F8-45A6-9532-82F11533CB27Q30202032-3ECA1376-14EB-4C61-BB19-1AE6829889F6Q30209583-848A353A-BEE4-4333-9EEA-AA09CED7EC0FQ30210097-B2B3B29F-DA76-465F-902F-749348880FF8Q30223838-5357E240-B92A-4610-BDE8-50DA43907862Q30352121-EBE3BF30-4073-4C09-A7DD-64ABAC9BAA5DQ30352315-140ADC94-501F-4601-B602-5C4F34CC7EEEQ30352329-B19FC5AF-7B47-43C6-B130-D0DA0464DC9EQ30352889-F6BACC5F-F19F-4711-846E-ECC8CDDEB916Q30353675-623BB79B-8274-48C9-81A3-FAD268B61CF1Q30356910-1F2A9EC9-9B1F-4230-9A22-62112768F4A7Q30359243-266F5068-4B75-4EF3-B425-EBBFC4E80920Q30359247-86E65E1F-439E-4673-A7C7-D2DF722BDB74Q30360483-64B9B162-C7EA-4AB7-AE0C-3650ACA09B09Q30360897-C2C80EDB-C22A-40D7-B6F6-5CE6BB612430Q30362536-AF0546D7-7FC1-4B1F-B95E-38C2E1353ACBQ30364635-5DB84C44-4C0F-43C3-90F9-663E2EC70F8CQ30364889-CDAFF68A-FED1-4B40-AA79-CE781A8B07CFQ30366806-854DDD40-8740-4BF0-8191-D0F4F304899EQ30367259-4C6B4068-FA14-4C5E-86C7-B14BE3395D77Q30367263-75C15B8B-9039-4CA6-ADBC-7492ECE569A5Q30367603-91FADDCF-67D2-4E05-8E95-BED4E8D95BE0Q30369467-A0F4F48E-613D-4E8A-9827-58B9E7E78B9DQ30369654-02E9DC85-AF68-4FB9-AB55-2503434B5FF2Q30370632-BAA8B209-F74E-48BA-9BBD-D4B708152FB4Q30371742-7EBB58A7-2EE6-4314-96D6-B05B6ABEF55B
P2860
AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
AS03 adjuvanted AH1N1 vaccine ...... hildhood narcolepsy in Finland
@ast
AS03 adjuvanted AH1N1 vaccine ...... hildhood narcolepsy in Finland
@en
AS03 adjuvanted AH1N1 vaccine ...... hildhood narcolepsy in Finland
@nl
type
label
AS03 adjuvanted AH1N1 vaccine ...... hildhood narcolepsy in Finland
@ast
AS03 adjuvanted AH1N1 vaccine ...... hildhood narcolepsy in Finland
@en
AS03 adjuvanted AH1N1 vaccine ...... hildhood narcolepsy in Finland
@nl
prefLabel
AS03 adjuvanted AH1N1 vaccine ...... hildhood narcolepsy in Finland
@ast
AS03 adjuvanted AH1N1 vaccine ...... hildhood narcolepsy in Finland
@en
AS03 adjuvanted AH1N1 vaccine ...... hildhood narcolepsy in Finland
@nl
P2093
P2860
P50
P3181
P1433
P1476
AS03 adjuvanted AH1N1 vaccine ...... hildhood narcolepsy in Finland
@en
P2093
Christer Hublin
Hanna Nohynek
Jonas Sundman
Jukka Jokinen
Outi Saarenpää-Heikkilä
Outi Vaarala
Päivi Olsén
Terhi Kilpi
Turkka Kirjavainen
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0033536
P407
P577
2012-01-01T00:00:00Z